According to previous medical opinion, chronic hepatitis B virus surface antigen (HBsAg) positive and chronic hepatitis C virus antibody positive individuals with normal liver function are called “healthy carriers”, who have been seropositive for more than 6 months, have no history of hepatitis, have no obvious signs and symptoms, and have normal liver function tests They have no history of hepatitis, no obvious symptoms and signs, and normal or basically normal liver function tests. For these patients, an observation and waiting approach is often adopted, and drug treatment is not advocated. In clinical practice, these people account for a considerable number of people, although most of them do not have a very poor prognosis and can live, study and work as usual, and a small number of hepatitis B surface antigen carriers can naturally turn negative with the strengthening of the body’s immunity, but this is not really a “healthy person” in the sense. Hepatitis B and C viruses can persist in people’s liver cells for years, decades, or even a lifetime, and there is a possibility of virus replication and transmission to others. In addition, with the development of medicine, pathological examination by liver aspiration has revealed that some hepatitis B surface antigen carriers and hepatitis C virus carriers have different degrees of inflammation and fibrosis in their liver tissues. More than 80% of the hepatitis C carriers have such pathological changes. Therefore, the term “healthy carriers” is gradually replaced by “asymptomatic chronic hepatitis B or C virus infected (or carriers)”. Moreover, a significant proportion of patients with cirrhosis may have no clear history of hepatitis B or C and develop from “asymptomatic hepatitis virus carriers”, whose symptoms and signs are usually not obvious and who do not pay attention to regular review. Cirrhosis of the liver. All of this cannot be explained by the word “health”. It can be seen that both “healthy carriers” and “asymptomatic hepatitis virus carriers” are not healthy, and are a situation between patients with current hepatitis and normal people. So, what should be done with “asymptomatic hepatitis carriers”? The only way is to review abdominal ultrasound, liver function, hepatitis B or C antibodies, HBV-DNA or HCV-RNA, and liver fibrosis indicators every six months to a year to detect and actively treat chronic hepatitis, liver fibrosis, and early cirrhosis to avoid the development of end-stage cirrhosis or even liver cancer. Of course, the most accurate test for potential lesions in “asymptomatic hepatitis virus carriers” is liver aspiration pathology, but because it is an invasive test, it is often not accepted. It is important to know that its early diagnostic value for those with liver disease and “asymptomatic hepatitis virus carriers” cannot be replaced by any other test. As long as there is inflammation and fibrosis on pathological histology, anti-inflammatory and anti-fibrotic treatment should be used, such as intravenous drip of glycine, salvia injection, etc. Once the pathology or serological examination is positive for HBV-DNA or HCV-RNA, antiviral treatment should be used, such as interferon, lamivudine, adefovir, etc.